ETNB

89bio, Inc. (ETNB) | Rumor.io

89bio

ETNB

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)99%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ETNB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Oct 30

89bio, Inc. (ETNB) has entered into 14 confidential agreements, but only found one suitor, indicating a challenging M&A process.
The company needs to achieve $4 billion in net sales for one of its CVR products within a year to receive a $6 payment, with the payment staggered and running until 2035.
Roche has purchased shares in a tender offer for 89bio, Inc. (ETNB), indicating a significant development for the company.

Generated by AI

Sentiment

Of the messages about ETNB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.27% -0.88
Bearish	—	—	—	5.73% +0.88

Bullish· Sep 18

$ETNB's market capitalization could increase from $372M to $2.5B by 2025, indicating significant growth potential.
The acquisition of $ETNB by Roche for $3.5B represents a 79% premium, providing a substantial return for long-term investors.
$ETNB's buyout by Roche may lead to increased activity in the MASH space, potentially benefiting other companies like $AKBA and $LCTX.

Bearish· Oct 10

The FDA's decision to grant Breakthrough Designation to 89bio, Inc. (ETNB) in NASH may not be enough to prevent a decline in the company's stock price, as investors are spooked by recent data from Akero Therapeutics (AKRO).
89bio, Inc. (ETNB) has been trending down, with a 36% decline, and is also loved by biopharma hedge funds, which may contribute to its volatility.
The recent mixed results from Akero Therapeutics (AKRO) have led to a significant decline in 89bio, Inc. (ETNB)'s stock price, with a 34.84% drop, as investors manage risk in the biotech sector.

Generated by AI

Topics

Of the messages about ETNB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.58%
Macro	—	—	—	1.57%
Earnings	—	—	—	0%
Controversies	—	—	—	1.01%
Announcements	—	—	—	94.47%
Analysts	—	—	—	0.37%

Analysts· Mar 23

89bio, Inc. (ETNB) has a strong buy consensus among analysts, with 89% of 14 analysts recommending a buy.
Analysts at HC Wainwright & Co. and Raymond James have raised their price targets for ETNB, with HC Wainwright & Co. targeting $30 and Raymond James targeting $50.
Analysts at HC Wainwright & Co. and Raymond James see significant upside potential for ETNB, with HC Wainwright & Co. estimating 110-114% upside and Raymond James estimating 250-257% upside.

Announcements· Oct 30

89bio, Inc. (ETNB) has completed a merger with Roche Holdings, with shareholders receiving $14.50 per share and potential additional payments through a contingent value right.
The merger includes a tender offer, with 94.1 million shares tendered, representing about 94% of outstanding shares.
Shareholders may receive up to $6.00 in contingent payments based on specific milestones following the merger.

Generated by AI

Community

Of the messages about ETNB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	57.89%	32.86%
Newcomers	—	—	42.11%	67.14%

Regulars· Sep 18

The acquisition of 89bio, Inc. (ETNB) by Roche is valued at up to $3.5 billion, with a cash payment of $14.50 per share and a non-tradeable CVR of $6.00 per share.
The F4 trial for 89bio's lead candidate, FGF21, is expected to complete by mid-2030, and the company faces competition from at least three other players in the market.
The deal's price and timing are being debated, with some questioning whether the business makes sense, and others pointing to the potential for expanded indications for FGF21.

Newcomers· Sep 18

The acquisition of 89bio, Inc. by Roche Holding is expected to be for up to $3.5 billion, with Roche offering $14.50 per share in cash.
Newcomers to the 89bio stock are discussing the company's oncolytic virus treatment, RP1, and the potential for FDA approval.
The acquisition by Roche is seen as a strategic move by the biopharmaceutical giant to expand its presence in the market through targeted acquisitions.

Generated by AI

Also Discussed

Investors talking about ETNB also mention

#	Name	Attention
1	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
2	TERN - Terns Pharmaceuticals, Inc.	——
3	MTSR - Metsera, Inc.	——
4	HARP - Harpoon Therapeutics, Inc.	——
5	Janux Therapeutics, Inc.JANX	0%0
6	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
7	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
8	IGMS - IGM Biosciences, Inc.	——
9	SWTX - SpringWorks Therapeutics, Inc.	——
10	AKRO - Akero Therapeutics, Inc.	——

89bio, Inc.

Location

Social

What share of all stock conversation is about ETNB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Oct 30

89bio, Inc. (ETNB) has entered into 14 confidential agreements, but only found one suitor, indicating a challenging M&A process.
The company needs to achieve $4 billion in net sales for one of its CVR products within a year to receive a $6 payment, with the payment staggered and running until 2035.
Roche has purchased shares in a tender offer for 89bio, Inc. (ETNB), indicating a significant development for the company.

Generated by AI

Sentiment

Of the messages about ETNB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.27% -0.88
Bearish	—	—	—	5.73% +0.88

Bullish· Sep 18

$ETNB's market capitalization could increase from $372M to $2.5B by 2025, indicating significant growth potential.
The acquisition of $ETNB by Roche for $3.5B represents a 79% premium, providing a substantial return for long-term investors.
$ETNB's buyout by Roche may lead to increased activity in the MASH space, potentially benefiting other companies like $AKBA and $LCTX.

Bearish· Oct 10

The FDA's decision to grant Breakthrough Designation to 89bio, Inc. (ETNB) in NASH may not be enough to prevent a decline in the company's stock price, as investors are spooked by recent data from Akero Therapeutics (AKRO).
89bio, Inc. (ETNB) has been trending down, with a 36% decline, and is also loved by biopharma hedge funds, which may contribute to its volatility.
The recent mixed results from Akero Therapeutics (AKRO) have led to a significant decline in 89bio, Inc. (ETNB)'s stock price, with a 34.84% drop, as investors manage risk in the biotech sector.

Generated by AI

Topics

Of the messages about ETNB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	2.58%
Macro	—	—	—	1.57%
Earnings	—	—	—	0%
Controversies	—	—	—	1.01%
Announcements	—	—	—	94.47%
Analysts	—	—	—	0.37%

Analysts· Mar 23

89bio, Inc. (ETNB) has a strong buy consensus among analysts, with 89% of 14 analysts recommending a buy.
Analysts at HC Wainwright & Co. and Raymond James have raised their price targets for ETNB, with HC Wainwright & Co. targeting $30 and Raymond James targeting $50.
Analysts at HC Wainwright & Co. and Raymond James see significant upside potential for ETNB, with HC Wainwright & Co. estimating 110-114% upside and Raymond James estimating 250-257% upside.

Announcements· Oct 30

89bio, Inc. (ETNB) has completed a merger with Roche Holdings, with shareholders receiving $14.50 per share and potential additional payments through a contingent value right.
The merger includes a tender offer, with 94.1 million shares tendered, representing about 94% of outstanding shares.
Shareholders may receive up to $6.00 in contingent payments based on specific milestones following the merger.

Generated by AI

Community

Of the messages about ETNB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	57.89%	32.86%
Newcomers	—	—	42.11%	67.14%

Regulars· Sep 18

The acquisition of 89bio, Inc. (ETNB) by Roche is valued at up to $3.5 billion, with a cash payment of $14.50 per share and a non-tradeable CVR of $6.00 per share.
The F4 trial for 89bio's lead candidate, FGF21, is expected to complete by mid-2030, and the company faces competition from at least three other players in the market.
The deal's price and timing are being debated, with some questioning whether the business makes sense, and others pointing to the potential for expanded indications for FGF21.

Newcomers· Sep 18

The acquisition of 89bio, Inc. by Roche Holding is expected to be for up to $3.5 billion, with Roche offering $14.50 per share in cash.
Newcomers to the 89bio stock are discussing the company's oncolytic virus treatment, RP1, and the potential for FDA approval.
The acquisition by Roche is seen as a strategic move by the biopharmaceutical giant to expand its presence in the market through targeted acquisitions.

Generated by AI

89bio

Social

Oct 30

Sentiment

Bullish· Sep 18

Bearish· Oct 10

Topics

Analysts· Mar 23

Announcements· Oct 30

Community

Regulars· Sep 18

Newcomers· Sep 18

Also Discussed

89bio, Inc.

Company Information

Location

Also Discussed

Social

Oct 30

Sentiment

Bullish· Sep 18

Bearish· Oct 10

Topics

Analysts· Mar 23

Announcements· Oct 30

Community

Regulars· Sep 18

Newcomers· Sep 18